• BridgeBio Pharma recently reported strong late-stage clinical data for acoramidis in transthyretin amyloid cardiomyopathy and encaleret in autosomal dominant hypocalcemia type 1, alongside submitting a New Drug Application to the FDA for encaleret.
• These advances suggest BridgeBio is moving beyond a single-product story, with encaleret potentially adding a second rare-disease franchise alongside Attruby.
• We’ll now examine how the positive encaleret NDA submission and ADH1 data could reshape BridgeBio’s existing investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 46 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

BridgeBio Pharma Investment Narrative Recap

To own BridgeBio today, you need to believe it can turn its rare disease pipeline into multiple commercial franchises while managing high cash burn and competition around Attruby. The encaleret NDA and CALIBRATE data slightly rebalance that equation in the near term, adding a potential second meaningful product but not removing the key risks of heavy Attruby dependence and ongoing operating losses.

The most relevant update is the NDA submission for encaleret in ADH1, backed by Phase 3 data showing 76% of patients reaching target calcium levels versus 4% on conventional therapy. If approved and launched as guided, encaleret could become BridgeBio’s first non-ATTR commercial pillar and an important proof point that its broader rare-disease thesis can translate into an additional, revenue-generating franchise.

Yet, even with these advances, investors still need to consider the risk that high operating expenses, potential trial setbacks, and future capital needs could...

BridgeBio Pharma's narrative projects $2.4 billion revenue and $758.3 million earnings by 2029.

Uncover how BridgeBio Pharma's forecasts yield a $100.89 fair value, a 46% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already projecting revenues of about US$3.4 billion and earnings of around US$1.3 billion, which is far more upbeat than consensus and assumes multiple pipeline wins; with encaleret’s new data and filing, you can see how opinions on whether those aggressive targets are realistic might widen further, so it is worth comparing how comfortable you are with that bolder story against more cautious views.

Explore 9 other fair value estimates on BridgeBio Pharma - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your BridgeBio Pharma research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free BridgeBio Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BridgeBio Pharma's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.